@article {Marchetti1058, author = {Claudia Marchetti and Francesca De Felice and Raffaella Ergasti and Giovanni Scambia and Anna Fagotti}, title = {Letrozole in the management of advanced ovarian cancer: an old drug as a new targeted therapy}, volume = {30}, number = {7}, pages = {1058--1064}, year = {2020}, doi = {10.1136/ijgc-2019-001128}, publisher = {BMJ Specialist Journals}, abstract = {At present, there is no standard of care on the use of letrozole in ovarian cancer management. We performed a systematic review of the available literature addressing this issue. Data demonstrated a role for letrozole in ovarian cancer, in both the primary and recurrent setting. Letrozole, which has a favorable toxicity profile, seems to assure a prolonged recurrence-free interval, particularly when used as maintenance treatment, in low grade serous ovarian cancer; in recurrent cases it had also led to prolonged disease control. However, the optimal setting and biologically relevant patient population needs to be defined in larger trials.}, issn = {1048-891X}, URL = {https://ijgc.bmj.com/content/30/7/1058}, eprint = {https://ijgc.bmj.com/content/30/7/1058.full.pdf}, journal = {International Journal of Gynecologic Cancer} }